Article Text

PDF
FRI0287 High Rate of Improvement in Serum Matrix Metalloproteinase-3 Levels at 4 Weeks PREDICT Remission at 52 Weeks in RA Patients with Anti-TNF Therapy
  1. Y. Hattori1,
  2. A. Kaneko1,
  3. D. Kida1,
  4. N. Takahashi2,
  5. H. Ishikawa1,
  6. H. Kanda1,
  7. T. Sato1,
  8. T. Kojima2,
  9. N. Ishiguro2
  1. 1Department of Orthopaedic Surgery and Rheumatology, National Hospital Organization Nagoya Medical Center
  2. 2Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

Abstract

Background Serum Matrix metalloproteinase-3 (MMP-3) is a specific inflammatory marker of the synovium in patients with rheumatoid arthritis (RA).

Objectives Our aim in this study is to investigate whether serum MMP-3 is the predictor for remission in treatment for RA patients with biologics.

Methods All RA patients (n=269) who underwent Adalimumab (ADA) treatment in the multicenter study group (Tsurumai Biologics Communication Registry; TBCR) were enrolled in this study. We analyzed 114 patients in continuation with ADA therapy for 52 weeks. We divided into 2 groups based on the improvement of serum level of MMP-3 and CRP: high rate of improvement (MMP-HR group) and low rate of improvement (MMP-LR group) in serum MMP-3 levels at 4 weeks, and: high rate of improvement (CRP-HR group) and low rate of improvement (CRP-LR group) in serum CRP levels at 4 weeks (Table 1). We also divided into 2 groups based on the serum level of MMP-3 and CRP: high value (MMP-H group) and low value (MMP-LR group) in serum MMP-3 levels at 4 weeks, and: high value (CRP-H group) and low value (CRP-L group) in serum CRP levels at 4 weeks (Table 2). We evaluated the rate of remission at 24, and 52 weeks in 2 groups.

Results In patients continuing at 52 weeks, the rate of remission at 24 and 52 weeks in MMP-HR group is 56% and 60%, and MMP-LR group is 32% and 37%. The rate of remission at 24 and 52 weeks in MMP-HR group is significantly higher than in MMP-LR group (Fig. 1). However, the rate of remission at 24 and 52 weeks had no significance in CRP-HR group and CRP-LR group (Fig. 2).The rate of remission at 24 and 52 weeks in MMP-H group is 35% and 44%, and MMP-L group is 55% and 53%. The rate of remission at 24 weeks in MMP-L group is significantly higher than in MMP-H group (Fig. 3). However, the rate of remission at 24 and 52 weeks had no significance in CRP-H group and CRP-L group (Fig. 4). Moreover, the rate of remission at 24 and 52 weeks in MMP-(L and HR) group is very high (Fig. 5). In patients continuing at 52 weeks, the best cut-off rate of improvement in MMP-3 at 4 weeks for determining remission at 52 weeks was 40% determined by ROC analysis (sensitivity: 47%, specificity: 83%, accuracy: 64%).

Conclusions We considered that high rate of improvement in serum MMP-3 at 4 weeks can be useful for predicting the remission at 52 weeks in RA patients with ADA therapy.

Disclosure of Interest Y. Hattori: None declared, A. Kaneko: None declared, A. Kaneko: None declared, D. Kida: None declared, D. Kida: None declared, N. Takahashi: None declared, N. Takahashi: None declared, H. Ishikawa: None declared, H. Ishikawa: None declared, H. Kanda: None declared, H. Kanda: None declared, T. Sato: None declared, T. Sato: None declared, T. Kojima Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, T. Kojima Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, N. Ishiguro Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, N. Ishiguro Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer

DOI 10.1136/annrheumdis-2014-eular.1957

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.